Figure 1.
Figure 1. Gene mutation distribution according to treatment arm. No difference in the frequency of gene mutations and mutated pathway groups before initiation of the study treatment was observed when comparing TN patients vs R patients. NOTCH signaling pathway: NOTCH1, SPEN, FBXW7; inflammatory/B-cell receptor pathway: BIRC3, EGR2, NFKBIE, KRAS, SAMHD1, BRAF; WNT signaling pathway: MGA, MED12, FBXW7; DNA damage and cell cycle control pathway: TP53, ATM, POT1, BRCC3, RB1; chromatin modification pathway: ZMYM3, IKZF3, ASXL1, CREBBP, SP140, KM2TC; and RNA and ribosomal processing pathway: SF3B1, XPO1.

Genemutation distribution according to treatment arm. No difference in the frequency of gene mutations and mutated pathway groups before initiation of the study treatment was observed when comparing TN patients vs R patients. NOTCH signaling pathway: NOTCH1, SPEN, FBXW7; inflammatory/B-cell receptor pathway: BIRC3, EGR2, NFKBIE, KRAS, SAMHD1, BRAF; WNT signaling pathway: MGA, MED12, FBXW7; DNA damage and cell cycle control pathway: TP53, ATM, POT1, BRCC3, RB1; chromatin modification pathway: ZMYM3, IKZF3, ASXL1, CREBBP, SP140, KM2TC; and RNA and ribosomal processing pathway: SF3B1, XPO1.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal